Korro to Participate in Upcoming Investor Conferences
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
马萨诸塞州剑桥市，2024年11月21日（环球新闻）-- Korro Bio, Inc.（Korro）（纳斯达克：KRRO）是一家临床阶段生物制药公司，专注于开发一种基于RNA编辑的新型基因药物，旨在治疗稀有和高发疾病，今天宣布管理层成员将参加以下投资者会议：
Piper Sandler 36th Annual Healthcare Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conference.
派杰投资第36届医疗保健年会
首席执行官兼总裁Ram Aiyar博士将于2024年12月3日星期二，下午4:00（东部时间）参与一个炉边谈话。首席财务官Vineet Agarwal和首席医疗官Kemi Olugemo万博士，FAAN，也将在会议上参加1对1的投资者会议。
7th Annual Evercore ISI HealthCONx Conference
Dr. Aiyar will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30 a.m. ET. Mr. Agarwal and Dr. Olugemo will also be participating at the conference.
第7届Evercore ISI HealthCONx会议
Aiyar博士将于2024年12月4日星期三，上午7:30（东部时间）参与一个炉边谈话。Agarwal先生和Olugemo博士也将参加会议。
Citi's 2024 Global Healthcare Conference
Dr. Aiyar, Mr. Agarwal, and Dr. Olugemo will participate in 1x1 investor meetings on Thursday, December 5, 2024.
花旗银行2024年全球医疗保健会议
Aiyar博士、Agarwal先生和Olugemo博士将于2024年12月5日（星期四）参加一对一的投资者会议。
Oppenheimer Movers in Rare Disease Summit
Dr. Aiyar will participate in a panel titled "Recent Progress on RNA Editing" on Thursday, December 12, 2024, at 3:40 p.m. ET. Mr. Agarwal will also be participating at the conference.
Oppenheimer在罕见疾病峰会中的 Movers
Aiyar博士将于2024年12月12日（星期四）下午3:40（东部时间）参与一个名为“RNA编辑的最新进展”的小组讨论。Agarwal先生也将参与此次会议。
The live webcasts of the Piper Sandler and Evercore fireside chats can be accessed on the "Events & Presentations" page in the Investor section of Korro's website at . Following the presentations, a replay of the event will be available for 30 days.
派杰投资和evercore的炉边聊天的现场直播可以在Korro网站投资者部分的“活动与演示”页面访问。演示结束后，活动的重播将在30天内提供。
About Korro
关于Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro是一家临床阶段的生物制药公司，专注于开发一种新型基因药物，用于治疗罕见和高发疾病，采用其专有的RNA编辑平台。Korro正在生成一系列差异化的项目，旨在利用身体的自然RNA编辑过程，影响精准而短暂的单碱基编辑。通过编辑RNA而不是DNA，Korro正在扩大基因药物的应用范围，提供额外的精确度和可调性，这可能会提高特异性和长期耐受性。利用基于寡核苷酸的方法，Korro预计将通过利用其专有平台与前所未有的递送方式、制造专业知识以及已建立的已批准寡核苷酸药物的监管途径，将其药物带给患者。Korro总部位于马萨诸塞州的剑桥市。如需更多信息，请访问korrobio.com。
Korro Contact Information
Korro联系信息：IR@korrobio.com
Investor & Media Contact
Tim Palmer
IR@korrobio.com
投资者和媒体联系人
Tim Palmer
Glenn.silver@finnpartners.com
